LEAN Project: Weight Loss and Appetite Suppression
Phase 1
Completed
- Conditions
- Weight Loss
- Registration Number
- NCT00153790
- Lead Sponsor
- The Cooper Institute
- Brief Summary
The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.
- Detailed Description
Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
- 30-45 years, women, overweight or obese class I, premenopausal, maintain current diet and exercise regimen
Exclusion Criteria
- pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Weight Loss Appetite Suppression
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Cooper Institute
🇺🇸Dallas, Texas, United States